A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer
To explore a reasonable and effective way to reduce the incidence of grade 3 or above diarrhea caused by pyrotinib
Breast Cancer
DRUG: Trastuzumab+pyrotinib+taxene
Incidence of ≥ grade 3 diarrhea, Incidence of ≥ grade 3 diarrhea, Up to 2 years
To explore a reasonable and effective way to reduce the incidence of grade 3 or above diarrhea caused by pyrotinib